Antimicrobial Agents and Chemotherapy · 2010 · 63 citations · 30 references
Life SciencesPharmacologyPharmacotherapyMolecular PharmacologyMolecular VirologyVirologyAntiretroviral TherapyAntiviral AgentsAntiviral Drug ResistanceAntiviral ResistanceAntiviral TherapyEnzyme InhibitionDrug Resistance MutationsHighly Active Antiretroviral TherapyHiv Antiretroviral TherapyNon-nucleoside InhibitorsNon-nucleoside Reverse Transcriptase InhibitorsNonnucleoside InhibitorsReverse Transcriptase Inhibitor ResistanceSelectivity
The nonnucleoside reverse transcriptase inhibitors (NNRTIs) are key components of highly active antiretroviral therapy (HAART) for the treatment of human immunodeficiency virus type 1 (HIV-1). A major problem with the first approved NNRTIs was the emergence of mutations in the HIV-1 reverse transcriptase (RT), in particular K103N and Y181C, which led to resistance to the entire class. We adopted an iterative strategy to synthesize and test small molecule inhibitors from a chemical series of pyrazoles against wild-type (wt) RT and the most prevalent NNRTI-resistant mutants. The emerging candidate, lersivirine (UK-453,061), binds the RT enzyme in a novel way (resulting in a unique resistance profile), inhibits over 60% of viruses bearing key RT mutations, with 50% effective concentrations (EC(50)s) within 10-fold of those for wt viruses, and has excellent selectivity against a range of human targets. Altogether lersivirine is a highly potent and selective NNRTI, with excellent efficacy against NNRTI-resistant viruses.
30
Akio Adachi, Howard E. Gendelman, Scott Koenig et al. · Journal of Virology · 1986 · 2.9K citations · Full text
UPDATE ON DRUG RESISTANCE MUTATIONS IN HIV-1
&NA; · Infectious Diseases in Clinical Practice · 2001 · 1.7K citations